Incyte Raises 2026 Revenue Outlook by $360M After CMS Settlement, Q2 EPS Crushes Estimates
INCY sits 71% above its 52-week low of $69.695.
Summary
Incyte lifted its 2026 revenue guidance to $5.13B-$5.26B, up from $4.77B-$4.94B, driven by a CMS settlement that adds $300M-$310M to Opzelura net sales. Q2 adjusted EPS of $3.09 demolished the $2.10 consensus, boosted by a $246M non-cash benefit from the settlement. Total Q2 net sales jumped 40% to $1.49B, with Jakafi at $816.7M and Opzelura at $449.7M. The company also discontinued the INCB160058 blood cancer program, a setback that was largely expected. This follows the June 22 settlement announcement and the recent Vega Therapeutics acquisition close. The guidance raise and earnings beat signal strong commercial execution and a favorable regulatory resolution.
At the time of this announcement, INCY was trading at $119.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $69.70 to $120.71. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.